Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The analysis of the drugs associated with these UMDs (Figure 3, left column) revealed that six of the ten most prevalent drugs were Group A drugs (cholecalciferol, ramipril, bisoprolol, pantoprazole, levothyroxine and torasemide), indicating their relevance for documentation and in-hospital prescription.

Source: 3.4. Unintended Medication Discrepancies. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

REAMINAS: A Retrospective Study Evaluating the Completeness of the Emergency Department’s Admission Medication and Its Influence on Discharge Medication

Study design awaiting verification · Journal of Clinical Medicine · 2026

Original publication title

REAMINAS: A Retrospective Study Evaluating the Completeness of the Emergency Department’s Admission Medication and Its Influence on Discharge Medication

Ludwig vom Hofe; Maximilian Günther; Daniela Huttner; Ute Amann; Jan Rémi; Matthias Klein; Dorothea Strobach

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Documentation of admission medication is frequently insufficient, particularly in the emergency department (ED). This study analyses discrepancies between the admission medication by ED physicians and pharmaceutical medication reconciliation (PMR) at the emergency admission ward, their clinical relevance, and influence on discharge medication.

Methods:

In a retrospective observational study (May 2022: April 2023) on an interdisciplinary emergency admission ward, unintended medication discrepancies (UMDs) between ED admission medication and PMR, as well as prescription discrepancies (PDs) between admission medication prescribed at the emergency admission ward and PMR, were analysed. Persistence of PDs up to discharge was evaluated. Drugs associated with discrepancies were classified for clinical relevance during hospitalisation as (A) relevant for documentation and prescription, (B) relevant for documentation but irrelevant for prescription, or (C) irrelevant for documentation and prescription. Additionally, a list of high-risk drugs was established.

Results:

For 256 patients, a median of three (Q1: Q3 0 to 6.75) and five (2 to 8) drugs were documented as admission medication in the ED and PMR, respectively, with a median of two (1 to 5) UMDs per patient. For Group A drugs, the admission medication prescribed at the emergency admission ward compared to the PMR resulted in a median of one (0 to 3) PD per patient. Drug omission was most common (60.0 and 61.0% of UMDs and PDs, respectively). A total of 22.8% of UMDs and 23.8% of PDs concerned high-risk drugs. Of 215 PDs eligible for discharge analysis, 137 (63.7%) persisted up to the discharge letter.

Conclusions:

A considerable number of discrepancies were found between the admission medication in the ED and PMR. A substantial proportion of these were caused by high-risk drugs, highlighting their potential to harm patients. Discrepancies tend to persist throughout hospitalisation up to the discharge letter.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Documentation of admission medication is frequently insufficient, particularly in the emergency department (ED). This study analyses discrepancies between the admission medication by ED physicians and pharmaceutical medication reconciliation (PMR) at the emergency admission ward, their clinical relevance, and influence on discharge medication.

Source: Background

Abstract: Results

For 256 patients, a median of three (Q1: Q3 0 to 6.75) and five (2 to 8) drugs were documented as admission medication in the ED and PMR, respectively, with a median of two (1 to 5) UMDs per patient. For Group A drugs, the admission medication prescribed at the emergency admission ward compared to the PMR resulted in a median of one (0 to 3) PD per patient. Drug omission was most common (60.0 and 61.0% of UMDs and PDs, respectively). A total of 22.8% of UMDs and 23.8% of PDs concerned high-risk drugs. Of 215 PDs eligible for discharge analysis, 137 (63.7%) persisted up to the discharge letter.

Source: Results

Abstract: Conclusions

A considerable number of discrepancies were found between the admission medication in the ED and PMR. A substantial proportion of these were caused by high-risk drugs, highlighting their potential to harm patients. Discrepancies tend to persist throughout hospitalisation up to the discharge letter.

Source: Conclusions
Authors’ abstract

Background:

Documentation of admission medication is frequently insufficient, particularly in the emergency department (ED). This study analyses discrepancies between the admission medication by ED physicians and pharmaceutical medication reconciliation (PMR) at the emergency admission ward, their clinical relevance, and influence on discharge medication.

Methods:

In a retrospective observational study (May 2022: April 2023) on an interdisciplinary emergency admission ward, unintended medication discrepancies (UMDs) between ED admission medication and PMR, as well as prescription discrepancies (PDs) between admission medication prescribed at the emergency admission ward and PMR, were analysed. Persistence of PDs up to discharge was evaluated. Drugs associated with discrepancies were classified for clinical relevance during hospitalisation as (A) relevant for documentation and prescription, (B) relevant for documentation but irrelevant for prescription, or (C) irrelevant for documentation and prescription. Additionally, a list of high-risk drugs was established.

Results:

For 256 patients, a median of three (Q1: Q3 0 to 6.75) and five (2 to 8) drugs were documented as admission medication in the ED and PMR, respectively, with a median of two (1 to 5) UMDs per patient. For Group A drugs, the admission medication prescribed at the emergency admission ward compared to the PMR resulted in a median of one (0 to 3) PD per patient. Drug omission was most common (60.0 and 61.0% of UMDs and PDs, respectively). A total of 22.8% of UMDs and 23.8% of PDs concerned high-risk drugs. Of 215 PDs eligible for discharge analysis, 137 (63.7%) persisted up to the discharge letter.

Conclusions:

A considerable number of discrepancies were found between the admission medication in the ED and PMR. A substantial proportion of these were caused by high-risk drugs, highlighting their potential to harm patients. Discrepancies tend to persist throughout hospitalisation up to the discharge letter.

Publication and source details

Original title: REAMINAS: A Retrospective Study Evaluating the Completeness of the Emergency Department’s Admission Medication and Its Influence on Discharge Medication

Ludwig vom Hofe; Maximilian Günther; Daniela Huttner; Ute Amann; Jan Rémi; Matthias Klein; Dorothea Strobach

Journal of Clinical Medicine · 2026

* Correspondence: l.hofe@campus.lmu.de© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Stiftung Patient & Klinische Pharmazie, Munich, Germany B. Braun-Stiftung, Melsungen, Germanyhttps://ror.org/02eq6ye19 BBST-D-21-00019This study was funded by the Stiftung Patient & Klinische Pharmazie, Munich, Germany, and the B. Braun-Stiftung, Melsungen, Germany (No. BBST-D-21-00019).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:30:11.129000+00:00

DOI: 10.3390/jcm15103902 · PMC13207043